Top ▲


Disease ID:1251
Associated with:0 target
1 immuno-relevant ligand
Vitiligo is an autoimmune disease, in which immune-mediated destruction of melanoctyes causes depigmentation of the skin.
Database Links
Disease Ontology: DOID:12306
OMIM: 193200


No target related data available for Vitiligo


Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
programmed cell death 1 ligand 1 5
Immuno Disease Comments: PD-L1 fusion protein treatment has been shown to increase Treg abundance and reduce/reverse depigmentation development in Pmel-1 vitiligo mice.
Clinical Use: PD-L1 is an important immunopharmacological drug discovery target, as many types of cancer cells express this ligand [1-2,6] as a means of evading immune detection and destruction by T-cell-mediated responses. Three monoclonal antibodies directed against PD-L1 are approved cancer therapeutics. Additional reading: [4] and [3]. | View clinical data


Show »

1. Greaves P, Gribben JG. (2013) The role of B7 family molecules in hematologic malignancy. Blood, 121 (5): 734-44. [PMID:23223433]

2. Janakiram M, Abadi YM, Sparano JA, Zang X. (2012) T cell coinhibition and immunotherapy in human breast cancer. Discov Med, 14 (77): 229-36. [PMID:23114578]

3. Johnson DB, Rioth MJ, Horn L. (2014) Immune checkpoint inhibitors in NSCLC. Curr Treat Options Oncol, 15 (4): 658-69. [PMID:25096781]

4. Lu J, Lee-Gabel L, Nadeau MC, Ferencz TM, Soefje SA. (2015) Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. J Oncol Pharm Pract, 21 (6): 451-67. [PMID:24917416]

5. Miao X, Xu R, Fan B, Chen J, Li X, Mao W, Hua S, Li B. (2018) PD-L1 reverses depigmentation in Pmel-1 vitiligo mice by increasing the abundance of Tregs in the skin. Sci Rep, 8 (1): 1605. [PMID:29371688]

6. Tang PA, Heng DY. (2013) Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer. Curr Oncol Rep, 15 (2): 98-104. [PMID:23263823]